All In Biotech

Drug Trial Radar · NCT00358501

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients: A Historically-Controlled, Multi-Center Phase 3 Study to Determine Safety & Efficacy

Last checked: Nov 20, 2026Latest source record: Jan 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

134

Actual

Start

Jul 2006

Primary completion

Sep 2008

Study completion Mar 2015

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
FDA Office of Orphan Products Development
First posted
Aug 1, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to (1) demonstrate the efficacy and safety (toxicity) of 25 mg/kg/day of Defibrotide in patients with severe veno-occlusive disease (sVOD) and (2) evaluate serum and endothelial markers of veno-occlusive disease (VOD) through the analysis of blood samples.

Conditions

  • Severe Hepatic Veno-Occlusive Disease

Interventions

  • DefibrotideDrug

    Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival at Day+100 Following Hematopoietic Stem Cell TransplantTime frame: Day+100 post hematopoietic stem cell transplant
  2. Complete Response by Day+100 Post Hematopoietic Stem Cell TransplantTime frame: Day+100 post hematopoietic stem cell transplant

Locations

25 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Duarte, California

  • Site not named

    Palo Alto, California

  • Site not named

    Denver, Colorado

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Maywood, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Baltimore, Maryland

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Rochester, Minnesota

  • Site not named

    St Louis, Missouri

  • Site not named

    Omaha, Nebraska

  • Site not named

    Hackensack, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Durham, North Carolina

  • Site not named

    Columbus, Ohio

  • Site not named

    Portland, Oregon

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Houston, Texas

  • Site not named

    Seattle, Washington

  • Site not named

    Vancouver, British Columbia, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.